# Ozempic Update: Supply Stabilizes as New Benefits in Stroke Prevention & Addiction Treatment Emerge
Discover the latest breakthrough developments in the world of Ozempic in this comprehensive podcast episode. Learn how the recent supply shortage has finally stabilized in Australia, with Novo Nordisk confirming availability for both current and new type 2 diabetes patients. We explore groundbreaking research showing Ozempic's unexpected benefits beyond weight management - from improved stroke outcomes and reduced dementia risk to a remarkable 30% reduction in all-cause mortality.
The episode also delves into Ozempic's surprising new application in addiction treatment, with early reports from Caron Treatment Centers suggesting semaglutide may "obliterate" cravings in patients recovering from opioid and alcohol dependence. We balance these promising developments with important safety information about ongoing legal concerns regarding potential side effects like gastroparesis.
Whether you're currently taking Ozempic, considering it as a treatment option, or simply interested in the latest medical innovations, this episode provides essential insights into how this medication is reshaping our approach to metabolic health, neurological protection, and possibly even addiction therapy.
#Ozempic #WeightLossmedication #Type2Diabetes #GLP1 #Semaglutide #OzempicShortage #StrokePrevention #AddictionTreatment
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Discover the latest breakthrough developments in the world of Ozempic in this comprehensive podcast episode. Learn how the recent supply shortage has finally stabilized in Australia, with Novo Nordisk confirming availability for both current and new type 2 diabetes patients. We explore groundbreaking research showing Ozempic's unexpected benefits beyond weight management - from improved stroke outcomes and reduced dementia risk to a remarkable 30% reduction in all-cause mortality.
The episode also delves into Ozempic's surprising new application in addiction treatment, with early reports from Caron Treatment Centers suggesting semaglutide may "obliterate" cravings in patients recovering from opioid and alcohol dependence. We balance these promising developments with important safety information about ongoing legal concerns regarding potential side effects like gastroparesis.
Whether you're currently taking Ozempic, considering it as a treatment option, or simply interested in the latest medical innovations, this episode provides essential insights into how this medication is reshaping our approach to metabolic health, neurological protection, and possibly even addiction therapy.
#Ozempic #WeightLossmedication #Type2Diabetes #GLP1 #Semaglutide #OzempicShortage #StrokePrevention #AddictionTreatment
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome back to Navigating Ozepic, the podcast where we shine
a bright light on everything connected to ozepic, from fresh
medical findings to the ways it is reshaping lifestyles and health.
Today is July nineteenth, twenty twenty five, and this episode
focuses on the most urgent news and emerging themes from
the world of ozepic over the past seventy two hours.
(00:22):
Let us start with a significant development that will affect
many listeners worldwide, the ozepic supply shortage. According to the
Australian Therapeutic Goods Administration, as of July nineteenth, the supply
of azepic has finally stabilized after a turbulent period marked
by months of restricted availability. Novo Nordisk, the pharmaceutical company
(00:45):
behind azempic, now assures that both current and new patients
prescribed a zepic for type two diabetes should be able
to access the drug without previous limitations. While it may
still take a little time for stocks to fully replenish
in every farmer, supply restrictions have officially been lifted, a
relief for countless patients and clinicians who have struggled with
(01:07):
delayed treatment and uncertainty throughout this year. However, the agency
reminds us that ozempic should continue to be prescribed only
for its approved use in diabetes management, as there is
not yet a broader approval for general weight loss coverage
under the Pharmaceutical Benefit Scheme In Australia, Novo Nordisk advises
(01:27):
patients still facing issues finding ozepic to have their pharmacist
contact the company directly for up to date supply information.
In parallel, new research is cementing Ozepic's reputation as more
than just a diabetes or weight loss drug. On July seventeenth,
findings released by Medical Express and euric Alert indicate that
(01:48):
weight loss drugs like ozempic may play a larger role
in preventing neurological events such as strokes and minimizing their impact.
Scientists have found that patients prescribed ozempic who did suffer
strokes generally experienced better outcomes than those who were not
on these therapies. This research could mark a turning point
(02:10):
in how clinicians think about preventing and mitigating the impact
of stroke and related injuries to the brain, and may
push ozepic and related drugs further into the spotlight as
tools for not just metabolic health, but also neurological protection.
Building on these stroke findings, a major analysis published in
Jammer Network earlier this July confirmed that summer glutide, ozepic's
(02:33):
active ingredient is associated with a significantly lower risk of dementia, stroke,
and even all cause mortality in adults who have both
type two diabetes and obesity. The study concluded that these
drugs offer potential neuroprotective and cerebrovascular benefits that extend well
(02:53):
beyond just controlling blood sugar levels. As context, about seventeen
million Americans live with both diabetes and obesity, and both
conditions contribute significantly to the risk of neurodegenerative diseases like
dementia and parkinson disease. Earlier generation diabetes drugs helped control glucose,
(03:15):
but newer compounds such as semaglutide and trazepetide appear to
offer broader protection, sparking interest in their possible use as
preventive medicine for long standing neurological threats. This multifaceted benefit
is a major factor in Wyozepic has quickly become one
of the most sought after drugs worldwide. Another eye opening
(03:35):
result emerged from new research covered by Benefits Pro on
July six. Data revealed that drugs like ozenpic reduce the
all cause mortality rate by as much as thirty percent
for individuals living with obesity and type two diabetes. This
dramatic risk reduction not only boosts patient survival, but reinforces
the perception of these drugs as essential treatments in chronic
(03:57):
disease management. In an era where metabolic disorders account for
a growing share of health system burdens, therapies that extend
life and provide cross system protection could alter how we
approach prevent texture and treatment. But the story of ozepic
extends beyond numbers and disease categories. A new frontier has
opened up in the realm of mental health and addiction recovery.
(04:18):
As reported by stat News on July fourth, Karen Treatment Centers,
a top tier addiction facility in Pennsylvania, recently began prescribing
semaglutide for patients recovering from opioid and alcohol dependence. According
to clinical staff, summer glutide has obliterated cravings in some individuals,
offering unprecedented hope for those whose addiction did not respond
(04:38):
to standard therapies. Although these novel users remain off label
and require larger clinical trials, the early outcomes suggest a
surprising new role for ozepic and addressing compulsive behaviors well
beyond dieting and glucose control. Every new benefit, though, must
be weighed against potential risk. This week, it is important
to note rising concerns about siders effects, legal actions, and
(05:01):
the full safety profile of azempic as more people worldwide
start or continue long term treatment. According to Federal Lawyer
dot com, the volume of lawsuits against Novo Nordisk continues
to rise, much of it centered on reports of severe
side effects like gastroparesis, which causes paralysis of the stomach. Increasingly,
(05:22):
there are also claims tied to ilius and other serious
intestinal issues. Anyone experiencing symptoms like abdominal pain, constipation, persistent nausea,
or food intolerance after starting ozempic is strongly advised to
seek medical advice and possibly legal counsel. The ongoing multidistrict
litigation in the United States continues to move forward, which
(05:44):
means more clarity on The scope and nature of these
reported complications should emerge over the coming months. While rare
complications deserve serious attention, overall real world data so far
still supports the safe and effective use of ozepic for
its approved populations when proscps described and monitored responsibly. Regulatory agencies,
including the Food and Drug Administration, are keeping a close
(06:06):
watch and continue to review ongoing and emerging safety data.
Welcome back to Navigating Ozepic, the podcast where we shine
a bright light on everything connected to ozepic, from fresh
medical findings to the ways it is reshaping lifestyles and health.
Today is July nineteenth, twenty twenty five, and this episode
focuses on the most urgent news and emerging themes from
the world of ozepic over the past seventy two hours.
(00:22):
Let us start with a significant development that will affect
many listeners worldwide, the ozepic supply shortage. According to the
Australian Therapeutic Goods Administration, as of July nineteenth, the supply
of azepic has finally stabilized after a turbulent period marked
by months of restricted availability. Novo Nordisk, the pharmaceutical company
(00:45):
behind azempic, now assures that both current and new patients
prescribed a zepic for type two diabetes should be able
to access the drug without previous limitations. While it may
still take a little time for stocks to fully replenish
in every farmer, supply restrictions have officially been lifted, a
relief for countless patients and clinicians who have struggled with
(01:07):
delayed treatment and uncertainty throughout this year. However, the agency
reminds us that ozempic should continue to be prescribed only
for its approved use in diabetes management, as there is
not yet a broader approval for general weight loss coverage
under the Pharmaceutical Benefit Scheme In Australia, Novo Nordisk advises
(01:27):
patients still facing issues finding ozepic to have their pharmacist
contact the company directly for up to date supply information.
In parallel, new research is cementing Ozepic's reputation as more
than just a diabetes or weight loss drug. On July seventeenth,
findings released by Medical Express and euric Alert indicate that
(01:48):
weight loss drugs like ozempic may play a larger role
in preventing neurological events such as strokes and minimizing their impact.
Scientists have found that patients prescribed ozempic who did suffer
strokes generally experienced better outcomes than those who were not
on these therapies. This research could mark a turning point
(02:10):
in how clinicians think about preventing and mitigating the impact
of stroke and related injuries to the brain, and may
push ozepic and related drugs further into the spotlight as
tools for not just metabolic health, but also neurological protection.
Building on these stroke findings, a major analysis published in
Jammer Network earlier this July confirmed that summer glutide, ozepic's
(02:33):
active ingredient is associated with a significantly lower risk of dementia, stroke,
and even all cause mortality in adults who have both
type two diabetes and obesity. The study concluded that these
drugs offer potential neuroprotective and cerebrovascular benefits that extend well
(02:53):
beyond just controlling blood sugar levels. As context, about seventeen
million Americans live with both diabetes and obesity, and both
conditions contribute significantly to the risk of neurodegenerative diseases like
dementia and parkinson disease. Earlier generation diabetes drugs helped control glucose,
(03:15):
but newer compounds such as semaglutide and trazepetide appear to
offer broader protection, sparking interest in their possible use as
preventive medicine for long standing neurological threats. This multifaceted benefit
is a major factor in Wyozepic has quickly become one
of the most sought after drugs worldwide. Another eye opening
(03:35):
result emerged from new research covered by Benefits Pro on
July six. Data revealed that drugs like ozenpic reduce the
all cause mortality rate by as much as thirty percent
for individuals living with obesity and type two diabetes. This
dramatic risk reduction not only boosts patient survival, but reinforces
the perception of these drugs as essential treatments in chronic
(03:57):
disease management. In an era where metabolic disorders account for
a growing share of health system burdens, therapies that extend
life and provide cross system protection could alter how we
approach prevent texture and treatment. But the story of ozepic
extends beyond numbers and disease categories. A new frontier has
opened up in the realm of mental health and addiction recovery.
(04:18):
As reported by stat News on July fourth, Karen Treatment Centers,
a top tier addiction facility in Pennsylvania, recently began prescribing
semaglutide for patients recovering from opioid and alcohol dependence. According
to clinical staff, summer glutide has obliterated cravings in some individuals,
offering unprecedented hope for those whose addiction did not respond
(04:38):
to standard therapies. Although these novel users remain off label
and require larger clinical trials, the early outcomes suggest a
surprising new role for ozepic and addressing compulsive behaviors well
beyond dieting and glucose control. Every new benefit, though, must
be weighed against potential risk. This week, it is important
to note rising concerns about siders effects, legal actions, and
(05:01):
the full safety profile of azempic as more people worldwide
start or continue long term treatment. According to Federal Lawyer
dot com, the volume of lawsuits against Novo Nordisk continues
to rise, much of it centered on reports of severe
side effects like gastroparesis, which causes paralysis of the stomach. Increasingly,
(05:22):
there are also claims tied to ilius and other serious
intestinal issues. Anyone experiencing symptoms like abdominal pain, constipation, persistent nausea,
or food intolerance after starting ozempic is strongly advised to
seek medical advice and possibly legal counsel. The ongoing multidistrict
litigation in the United States continues to move forward, which
(05:44):
means more clarity on The scope and nature of these
reported complications should emerge over the coming months. While rare
complications deserve serious attention, overall real world data so far
still supports the safe and effective use of ozepic for
its approved populations when proscps described and monitored responsibly. Regulatory agencies,
including the Food and Drug Administration, are keeping a close
(06:06):
watch and continue to review ongoing and emerging safety data.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Cardiac Cowboys
The heart was always off-limits to surgeons. Cutting into it spelled instant death for the patient. That is, until a ragtag group of doctors scattered across the Midwest and Texas decided to throw out the rule book. Working in makeshift laboratories and home garages, using medical devices made from scavenged machine parts and beer tubes, these men and women invented the field of open heart surgery. Odds are, someone you know is alive because of them. So why has history left them behind? Presented by Chris Pine, CARDIAC COWBOYS tells the gripping true story behind the birth of heart surgery, and the young, Greatest Generation doctors who made it happen. For years, they competed and feuded, racing to be the first, the best, and the most prolific. Some appeared on the cover of Time Magazine, operated on kings and advised presidents. Others ended up disgraced, penniless, and convicted of felonies. Together, they ignited a revolution in medicine, and changed the world.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.